Company profile
Kiniksa Pharmaceuticals International, plc
NASDAQ:KNSABiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RILONACEPT | approved | — | 2 | approved |
| Abiprubart | phase2 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03980522 | phase2 | completed | 2018-01-24 | 2019-05-17 | Kiniksa Pharmaceuticals (UK), Ltd. | A Pilot Study of KPL-914 in Recurrent Pericarditis |
| NCT06531395 | phase2 | terminated | 2024-07-17 | 2025-03-06 | Kiniksa Pharmaceuticals International, plc | A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease |
| NCT03827018 | phase2 | completed | 2018-09-20 | 2020-08-13 | Kiniksa Pharmaceuticals, Ltd. | KPL-301 for Subjects With Giant Cell Arteritis |
| NCT07010159 | phase2_3 | recruiting | 2025-07-25 | 2027-12-31 | Kiniksa Pharmaceuticals International, plc | Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387 |
| NCT04447469 | phase2_3 | completed | 2020-07-28 | 2021-11-12 | Kiniksa Pharmaceuticals International, plc | Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 125249 | BLA | Kiniksa Pharmaceuticals (UK), Ltd. | ||||
Loading… | ||||||